Benzinga

Benzinga

Benzinga

domingo, agosto 23

BeOne Medicines Ltd

ONCNASDAQ
Trade with Public
Trade with Public
$374.47
5.311.44%
al cierre: Aug 21, 5:00 PM EST
$374.47
N/A
After hour: Aug 21, 4:21 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

BeOne Medicines Analyst Price Targets

Wall Street analyst price targets and consensus rating for BeOne Medicines (ONC).

Price Target Range — 7 Quarters

Analyst Consensus — 16 Analysts

2S.Buy
14Buy
Consensus RatingBuy# Analysts16Avg. Consensus PT$384Upside to Avg. PT+2.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 6, 2026TD CowenYaron WerberPT RaiseBuy$424→$454
Aug 6, 2026RBC CapitalLeonid TimashevPT CutOutperform$451→$450
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
TD Cowen Maintains Buy on BeOne Medicines, Raises Price Target to $454

TD Cowen analyst Yaron Werber maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $424 to $454.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on BeOne Medicines, Lowers Price Target to $450

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and lowers the price target from $451 to $450.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $418

Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $416 to $418.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $430

Guggenheim analyst Michael Schmitz maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $420 to $430.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $405

Citizens analyst Reni J. Benjamin maintains BeOne Medicines (NASDAQ:ONC) with a Market Outperform and raises the price target from $396 to $405.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $425

JP Morgan analyst Jessica Fye maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $415 to $425.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved